MX2023014663A - Terapias combinadas con inhibidores de setd2. - Google Patents
Terapias combinadas con inhibidores de setd2.Info
- Publication number
- MX2023014663A MX2023014663A MX2023014663A MX2023014663A MX2023014663A MX 2023014663 A MX2023014663 A MX 2023014663A MX 2023014663 A MX2023014663 A MX 2023014663A MX 2023014663 A MX2023014663 A MX 2023014663A MX 2023014663 A MX2023014663 A MX 2023014663A
- Authority
- MX
- Mexico
- Prior art keywords
- inhibitors
- therapeutic agent
- setd2
- combination therapies
- setd2 protein
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 4
- 238000002648 combination therapy Methods 0.000 title 1
- 239000003814 drug Substances 0.000 abstract 3
- 102100032742 Histone-lysine N-methyltransferase SETD2 Human genes 0.000 abstract 2
- 101000654725 Homo sapiens Histone-lysine N-methyltransferase SETD2 Proteins 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 abstract 2
- 229940121649 protein inhibitor Drugs 0.000 abstract 2
- 239000012268 protein inhibitor Substances 0.000 abstract 2
- 229940124597 therapeutic agent Drugs 0.000 abstract 2
- 229940124291 BTK inhibitor Drugs 0.000 abstract 1
- 229940124292 CD20 monoclonal antibody Drugs 0.000 abstract 1
- 229940124297 CDK 4/6 inhibitor Drugs 0.000 abstract 1
- 230000005971 DNA damage repair Effects 0.000 abstract 1
- 229940124087 DNA topoisomerase II inhibitor Drugs 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 102100025210 Histone-arginine methyltransferase CARM1 Human genes 0.000 abstract 1
- 239000012828 PI3K inhibitor Substances 0.000 abstract 1
- 239000000317 Topoisomerase II Inhibitor Substances 0.000 abstract 1
- 229940122803 Vinca alkaloid Drugs 0.000 abstract 1
- 239000002168 alkylating agent Substances 0.000 abstract 1
- 229940100198 alkylating agent Drugs 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 108010030886 coactivator-associated arginine methyltransferase 1 Proteins 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000002777 nucleoside Substances 0.000 abstract 1
- 150000003833 nucleoside derivatives Chemical class 0.000 abstract 1
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 abstract 1
- 229910052697 platinum Inorganic materials 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163208882P | 2021-06-09 | 2021-06-09 | |
| PCT/US2022/032718 WO2022261243A1 (en) | 2021-06-09 | 2022-06-08 | Combination therapies with setd2 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023014663A true MX2023014663A (es) | 2024-05-08 |
Family
ID=84425539
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023014663A MX2023014663A (es) | 2021-06-09 | 2022-06-08 | Terapias combinadas con inhibidores de setd2. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240299352A1 (enExample) |
| EP (1) | EP4351552A4 (enExample) |
| JP (1) | JP2024522184A (enExample) |
| KR (1) | KR20240019241A (enExample) |
| CN (1) | CN117794543A (enExample) |
| AU (1) | AU2022288073A1 (enExample) |
| CA (1) | CA3221071A1 (enExample) |
| IL (1) | IL308868A (enExample) |
| MX (1) | MX2023014663A (enExample) |
| WO (1) | WO2022261243A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL272379B2 (en) | 2017-08-14 | 2025-11-01 | Epizyme Inc | Methods of treating cancer by inhibiting setd2 |
| JP7627209B2 (ja) | 2018-08-14 | 2025-02-05 | エピザイム，インコーポレイティド | 置換インドール及びその使用方法 |
| CN121695288A (zh) | 2020-02-19 | 2026-03-20 | Epizyme股份有限公司 | Setd2抑制剂和相关方法和用途，包括组合疗法 |
| WO2025034951A1 (en) * | 2023-08-09 | 2025-02-13 | Enanta Pharmaceuticals, Inc. | Pharmaceutical compounds and compositions as c-kit kinase inhibitors |
| TW202532067A (zh) * | 2023-12-13 | 2025-08-16 | 大陸商正大天晴藥業集團股份有限公司 | 含有吡唑環及雙環雜芳基的化合物 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9446064B2 (en) * | 2013-03-14 | 2016-09-20 | Epizyme, Inc. | Combination therapy for treating cancer |
| WO2015150097A1 (en) * | 2014-04-04 | 2015-10-08 | Iomet Pharma Ltd | Indole derivatives for use in medicine |
| US20170232030A1 (en) * | 2014-08-13 | 2017-08-17 | Epizyme, Inc. | Combination therapy for treating cancer |
| US9717745B2 (en) * | 2015-03-19 | 2017-08-01 | Zhejiang DTRM Biopharma Co. Ltd. | Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases |
| IL272379B2 (en) * | 2017-08-14 | 2025-11-01 | Epizyme Inc | Methods of treating cancer by inhibiting setd2 |
| JP7627209B2 (ja) * | 2018-08-14 | 2025-02-05 | エピザイム，インコーポレイティド | 置換インドール及びその使用方法 |
| WO2020112872A1 (en) * | 2018-11-30 | 2020-06-04 | Epizyme, Inc. | Methods of treating whsc1-overexpressing cancers by inhibiting setd2 |
| CN121695288A (zh) * | 2020-02-19 | 2026-03-20 | Epizyme股份有限公司 | Setd2抑制剂和相关方法和用途，包括组合疗法 |
-
2022
- 2022-06-08 EP EP22820985.4A patent/EP4351552A4/en active Pending
- 2022-06-08 CN CN202280054248.9A patent/CN117794543A/zh active Pending
- 2022-06-08 MX MX2023014663A patent/MX2023014663A/es unknown
- 2022-06-08 CA CA3221071A patent/CA3221071A1/en active Pending
- 2022-06-08 US US18/568,368 patent/US20240299352A1/en active Pending
- 2022-06-08 KR KR1020247000394A patent/KR20240019241A/ko active Pending
- 2022-06-08 JP JP2023575830A patent/JP2024522184A/ja active Pending
- 2022-06-08 AU AU2022288073A patent/AU2022288073A1/en active Pending
- 2022-06-08 WO PCT/US2022/032718 patent/WO2022261243A1/en not_active Ceased
- 2022-06-08 IL IL308868A patent/IL308868A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4351552A4 (en) | 2025-06-18 |
| KR20240019241A (ko) | 2024-02-14 |
| US20240299352A1 (en) | 2024-09-12 |
| CN117794543A (zh) | 2024-03-29 |
| JP2024522184A (ja) | 2024-06-11 |
| CA3221071A1 (en) | 2022-12-15 |
| AU2022288073A1 (en) | 2023-12-07 |
| WO2022261243A1 (en) | 2022-12-15 |
| IL308868A (en) | 2024-01-01 |
| EP4351552A1 (en) | 2024-04-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Herman et al. | The Bruton tyrosine kinase (BTK) inhibitor acalabrutinib demonstrates potent on-target effects and efficacy in two mouse models of chronic lymphocytic leukemia | |
| Tsuji et al. | CC-115, a dual inhibitor of mTOR kinase and DNA-PK, blocks DNA damage repair pathways and selectively inhibits ATM-deficient cell growth in vitro | |
| Sembill et al. | Management of children and adolescents with chronic myeloid leukemia in blast phase: International pediatric CML expert panel recommendations: CHRONIC MYELOGENOUS LEUKEMIA | |
| Flinn et al. | A phase II trial to evaluate the efficacy of fostamatinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) | |
| Dervieux et al. | Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis | |
| Trottmann et al. | Semen quality in men with malignant diseases before and after therapy and the role of cryopreservation | |
| Jerkeman et al. | Targeting of B‐cell receptor signalling in B‐cell malignancies | |
| Choi et al. | Sublethal concentrations of 17-AAG suppress homologous recombination DNA repair and enhance sensitivity to carboplatin and olaparib in HR proficient ovarian cancer cells | |
| Choi et al. | Inhibitors of B-cell receptor signaling for patients with B-cell malignancies | |
| Macias-Perez et al. | GS-1101: a delta-specific PI3K inhibitor in chronic lymphocytic leukemia | |
| Flinn et al. | Combination trial of duvelisib (IPI‐145) with rituximab or bendamustine/rituximab in patients with non‐Hodgkin lymphoma or chronic lymphocytic leukemia | |
| Gruber et al. | Impact of tyrosine kinase inhibitors on patient outcomes in Philadelphia chromosome‐positive acute lymphoblastic leukaemia | |
| Oing et al. | Platinum-refractory germ cell tumors: an update on current treatment options and developments | |
| Mempel et al. | Combining precision oncology and immunotherapy by targeting the MALT1 protease | |
| Breitbach et al. | The selective inhibitor of nuclear export (SINE) verdinexor exhibits biologic activity against canine osteosarcoma cell lines | |
| Troussard et al. | The revised guidelines for the diagnosis and management of hairy cell leukaemia and the hairy cell leukaemia variant. | |
| Špaček et al. | Idelalisib plus rituximab versus ibrutinib in the treatment of relapsed/refractory chronic lymphocytic leukaemia: a real‐world analysis from the Chronic Lymphocytic Leukemia Patients Registry (CLLEAR) | |
| Olteanu et al. | Original clinical experience and approach to treatment study with interleukine 12/23 inhibitor in moderate-to-severe psoriasis patients | |
| Yu et al. | Upfront treatment with the first and second-generation tyrosine kinase inhibitors in Ph-positive acute lymphoblastic leukemia | |
| Tan et al. | A systematic review of the management of eosinophilic dermatosis of hematological malignancy | |
| Pettit et al. | Novel therapies for myelofibrosis | |
| Hadaschik et al. | Targeting prostate cancer with HTI‐286, a synthetic analog of the marine sponge product hemiasterlin | |
| Lin et al. | CXCL10-induced regulatory T cells and adenosine signaling promote immunosuppression and progression of epithelial ovarian cancer | |
| Dewani et al. | Poly (Adenosine Diphosphate Ribose) Polymerase (PARP) Inhibitors in the Treatment of Advanced Ovarian Cancer: A Narrative Review. | |
| Shaw et al. | Poor outcomes for trial‐ineligible patients receiving polatuzumab for relapsed/refractory diffuse large B‐cell lymphoma in routine care: An Australian Lymphoma and Related Diseases Registry project |